51,619 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Ceredex Value Advisors LLC

Ceredex Value Advisors LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, HoldingsChannel reports. The firm purchased 51,619 shares of the medical research company’s stock, valued at approximately $25,880,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. North Dakota State Investment Board bought a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $7,505,000. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $15,501,867,000. Hudson Value Partners LLC lifted its position in shares of Thermo Fisher Scientific by 24.9% during the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock valued at $8,349,000 after buying an additional 3,317 shares during the last quarter. Boston Trust Walden Corp increased its stake in shares of Thermo Fisher Scientific by 9.7% in the fourth quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock worth $25,480,000 after purchasing an additional 3,873 shares in the last quarter. Finally, Xponance LLC raised its holdings in Thermo Fisher Scientific by 8.1% during the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock valued at $34,358,000 after acquiring an additional 4,436 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent analyst reports. Royal Bank Of Canada boosted their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Barclays raised their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their target price for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Finally, Piper Sandler upped their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Lisa P. Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 63,493 shares of company stock worth $37,657,681 over the last ninety days. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Up 2.4%

NYSE:TMO opened at $628.24 on Friday. The firm has a market capitalization of $232.29 billion, a price-to-earnings ratio of 33.79, a price-to-earnings-growth ratio of 2.50 and a beta of 0.85. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99. The business has a fifty day moving average price of $539.33 and a 200-day moving average price of $508.86. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the company earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.